Impact of single nucleotide polymorphisms (SNPs) on immunosuppressive therapy in lung transplantation

International Journal of Molecular Sciences

Volumn 16, Issue 9, 2015, Pages 20168-20182

  Ruiz, Jesus ^a,b   Herrero, Maria José ^a,c   Bosó, Virginia ^a,b   Megías, Juan Eduardo ^a,b   Hervás, David ^a   Poveda, Jose Luis ^b   Escrivá, Juan ^b   Pastor, Amparo ^b   Solé, Amparo ^b   Aliño, Salvador Francisco ^a,b,c  

^a INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Lung transplantation; Mycophenolic acid; P glycoprotein; Pharmacogenetics; Tacrolimus

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CYTOCHROME P450 3A5; GLUCURONOSYLTRANSFERASE 1A9; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; TACROLIMUS; ABCB1 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2;

ARTICLE; BODY WEIGHT; FEMALE; GENOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; ADULT; ADVERSE EFFECTS; GENETICS; MIDDLE AGED; PHARMACOGENETICS;

ADULT; CYTOCHROME P-450 CYP3A; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MYCOPHENOLIC ACID; P-GLYCOPROTEINS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS;

EID: 84940093567     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160920168     Document Type: Article

References (54)

1. ISHLT Transplant Registry Quarterly Reports for Lung in Europe. Available online: https://www.ishlt.org/registries/quarterlyDataReportResults.asp?organ=LU&rptType=recip_p_sur v&continent=3 (accessed on 10 May 2015).
2. Studer, S.M.; Levy, R.D.; McNeil, K.; Orens, J.B. Lung transplant outcomes: A review of survival, graft function, physiology, health-related quality of life and cost-effectiveness. Eur. Respir. J. 2004, 24, 674-685.
3. Trindade, A.J.; Palmer, S.M. Current concepts and controversies in lung transplantation. Respir. Care Clin. N. Am. 2004, 10, 427-447.
4. Staatz, C.E.; Goodman, L.K.; Tett, S.E. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin. Pharmacokinet. 2010, 49, 141-175.
5. Dupuis, R.; Yuen, A.; Innocenti, F. The influence of UGT polymorphisms as biomarkers in solid organ transplantation. Int. J. Clin. Chem. 2012, 413, 1318-1325.
6. Wang, J.; Figurski, M.; Shaw, L.M.; Burckart, G.J. The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice. Transpl. Immunol. 2008, 19, 192-196.
7. Stingl, J.C.; Bartels, H.; Viviani, R.; Lehmann, M.L.; Brockmöller, J. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. Pharmacol. Ther. 2014, 141, 92-116.
8. Naesens, M.; Kuypers, D.R.; Verbeke, K.; Vanrenterghem, Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposition allograft recipients. Transplantation 2006, 1074-1084.
9. Ting, L.S.L.; Benoit-Biancamano, M.O.; Bernard, O.; Riggs, K.W.; Guillemette, C.; Ensom, M.H.H. Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: An exploratory study. Pharmacotherapy 2010, 30, 1097-1108.
10. Burckart, G.J.; Hutchinson, I.V.; Zeevi, A. Pharmacogenomics and lung transplantation: Clinical implications. Pharmacogenomics J. 2006, 6, 301-310.
11. Herrero, M.J.; Boso, V.; Rojas, L.; Bea, S.; Sanchez, J.; Hernandez, J.; Poveda, J.L.; Alino, S. Practical Pharmacogenetics and Single Nucleotide Polymorphisms (SNPs) in Renal Transplantation. In Current Issues and Future Direction in Kidney Transplantation, Rath T., Ed.; InTech Open Science: Valencia, Spain, 2013; pp: 287-307.
12. Staatz, C.E.; Goodman, L.K.; Tett, S.E. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin. Pharmacokinet. 2010, 49, 207-221.
13. Provenzani, A.; Santeusanio, A.; Mathis, E.; Notarbartolo, M.; Labbozzetta, M.; Poma, P.; Provenzani, A.; Polidori, C.; Vizzini, G.; Polidori, P.; et al. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World J. Gastroenterol. 2013, 19, 9156-9173.
14. Zaza, G.; Granata, S.; Tomei, P.; Dalla Gassa, A.; Lupo, A. Personalization of the immunosuppressive treatment in renal transplant recipients: The great challenge in “omics” medicine. Int. J. Mol. Sci. 2015, 16, 4281-4305.
15. Murray, B.; Hawes, E.; Lee, R.A.; Watson, R.; Roederer, M.W. Genes and beans: Pharmacogenomics of renal transplant. Pharmacogenomics 2013, 14, 783-798.
16. Monchaud, C.; Marquet, P. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: Part I. Clin. Pharmacokinet. 2009, 48, 419-462.
17. Bosò, V.; Herrero, M.J.; Buso, E.; Galan, J.; Almenar, L.; Sanchez-Lazaro, I. Genotype and allele frequencies of drug-metabolizing enzymes and drug transporter genes affecting immunosuppressants in the Spanish white population. Ther. DrugMonit. 2014, 36, 159-168.
18. Herrero, M.J.; Almenar, L.; Jordan, C.; Sanchez, I.; Poveda, J.L.; Aliňo, S.F. Clinical interest of pharmacogenetic polymorphisms in the immunosuppressive treatment after heart transplantation. Transplant. Proc. 2010, 42, 3181-3182.
19. Herrero, M.J.; Sánchez-Plumed, J.; Galiana, M.; Bea, S.; Marquès, M.R.; Aliňo, S.F. Influence of pharmacogenetic polymorphisms in routine immunosuppression therapy after renal transplantation. Transplant. Proc. 2010, 42, 3134-3136.
20. Cusinato, D.A.C.; Lacchini, R.; Romao, E.A.; -Ne Moysésto, M.; Coelho, E.B. Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients. Br. J. Clin. Pharmacol. 2014, 78, 364-372.
21. Kimchi-Sarfaty, C.; Gribar, J.J.; Gottesman, M.M. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol. 2002, 62, 1-6.
22. Sánchez-Lázaro, I.; Herrero, M.J.; Jordan-De Luna, C.; Bosò, V.; Almenar, L.; Rojas, L.; Martinez-Dolz, L.; Megias-Vericat, J.E.; Sendra, L.; Miguel, A.; et al. Association of single nucleotide polymorphisms to the efficacy and safety of immunosuppressant therapy after heart transplantation. Pharmacogenomics 2015, 24, 1-9.
23. Jordán de Luna, C.; Herrero Cervera, M.J.; Sánchez Lázaro, I.; Almenar Bonet, L.; Poveda Andrès, J.L.; Alino Pellicer, S.F. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels. Transplant. Proc. 2011, 43, 2241-2243.
24. Hesselink, D.A.; Bouamar, R.; Elens, L.; van Schaik, R.H.N; van Gelder, T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin. Pharmacokinet. 2014, 53, 123-139.
25. Rojas, L.E.; Herrero, M.J.; Boso, V.; Garcia-Eliz, M.; Poveda, J.L.; Librero, J. Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation. Pharmacogenet. Genomics 2013, 23, 509-517.
26. Rojas, L.; Neumann, I.; Herrero, M.J.; Bosò, V.; Reig, J.; Poveda, J.L.; Aliňo, S.F. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: A systematic review and meta-analysis of observational studies. Pharmacogenomics J. 2015, 15, 38-48.
27. Thervet, E.; Loriot, M.A.; Barbier, S.; Buchler, M.; Ficheux, M.; Choukroun, G.; Toupance, O.; Touchard, G.; Alberti, C.; Le Pogamp, P.; et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 2010, 87, 721-726.
28. Birdwell, K.A.; Decker, B.; Barbarino, J.M.; Peterson, J.F.; Stein, C.M.; Sadee, W.; Wang, D.; Vinks, A.A.; He, Y.; Swen, J.J.; et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin. Pharmacol. Ther. 2015, 98, 19-24.
29. Naito, T.; Mino, Y.; Aoki, Y.; Hirano, K.; Shimoyama, K.; Ogawa, N.; Kagawa, Y.; Kawakami, J. ABCB1 genetic variant and its associated tacrolimus pharmacokinetics affect renal function in patients with rheumatoid arthritis. Clin. Chim. Acta 2015, 445, 79-84.
30. Woodahl, E.L.; Ho, R.J.Y. The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr. DrugMetab. 2004, 5, 11-19.
31. Marzolini, C.; Paus, E.; Buclin, T.; Kim, R.B. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin. Pharmacol. Ther. 2004, 75, 13-33.
32. Wang, J.; Zeevi, A.; McCurry, K.; Schuetz, E.; Zheng, H.; Iacono, A. Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors. Transpl. Immunol. 2006, 15, 235-240.
33. Hesselink, D.A.; van Schaik, R.H.N.; van der Heiden, I.P.; van der Werf, M.; Gregoor, P.J.; Lindemans, J. Genetic polymorphisms of the CYP3A4; CYP3A5; and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 2003, 74, 245-254.
34. Haufroid, V.; Mourad, M.; van Kerckhove, V.; Wawrzyniak, J.; de Meyer, M.; Eddour, D.C. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004, 14, 147-154.
35. Zheng, H.; Zeevi, A.; Schuetz, E.; Lamba, J.; McCurry, K.; Griffith, B.P. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J. Clin. Pharmacol. 2004, 44, 135-140.
36. Mazidi, T.; Rouini, M.-R.; Ghahremani, M.-H.; Dashti-Khavidaki, S.; Lessan-Pezeshki, M.; Ahmadi, F.L. Impact of UGT1A9 polymorphism on mycophenolic acid pharmacokinetic parameters in stable renal transplant patients. Iran J. Pharm. Res. 2013, 12, 547-556.
37. Fukuda, T.; Goebel, J.; Cox, S.; Maseck, D.; Zhang, K.; Sherbotie, J.R. UGT1A9; UGT2B7; and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients. Ther. DrugMonit. 2012, 34, 671-679.
38. Ohmann, E.L.; Burckart, G.J.; Brooks, M.M.; Chen, Y.; Pravica, V.; Girnita, D.M. Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients. J. Heart Lung Transplant. 2010, 29, 509-516.
39. Woillard, J.-B.; Rerolle, J.-P.; Picard, N.; Rousseau, A.; Drouet, M.; Munteanu, E. Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: The significant role of the UGT1A8 2 variant allele. Brit. J. Clin. Pharmacol. 2010, 69, 675-683.
40. Burckart, G.J.; Figg, W.D.; Brooks, M.M.; Green, D.J.; Troutman, S.M.; Ferrell, R. Multi-institutional study of outcomes after pediatric heart transplantation: Candidate gene polymorphism analysis of ABCC2. J. Pediatr. Pharmacol. Ther. 2014, 19, 16-24.
41. Staatz, C.E, Tett, S.E Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin. Pharmacokinet. 2007, 46, 13-58.
42. Tsai, S.-J.; Hong, C.-J.; Yeh, H.-L.; Liou, Y.-J.; Yang, A.C.; Liu, M.-E. Heterozygote advantage of the MTHFR C677T polymorphism on specific cognitive performance in elderly Chinese males without dementia. Dement. Geriatr. Cogn. Disord. 2011, 32, 159-163.
43. Li, X.; Shao, M.; Wang, S.; Zhao, X.; Chen, H.; Qian, J. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Tumour Biol. 2014, 35, 11159-11170.
44. Zhang, W.X.; Chen, B.; Jin, Z.; Yu, Z.; Wang, X.; Chen, H.; Mao, A.; Cai, W. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. Xenobiotica 2008, 38, 1422-1436.
45. Michelon, H.; Konig, J.; Durrbach, A.; Quteineh, L.; Verstuyft, C.; Furlan, V. SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics 2010, 11, 1703-1713.
46. Sarangi, S.C.; Reeta, K.H.; Agarwal, S.K.; Kaleekal, T.; Guleria, S.; Gupta, Y.K. A pilot study on area under curve of mycophenolic acid as a guide for its optimal use in renal transplant recipients. Indian J. Med. Res. 2012, 135, 84-91.
47. Ningappa, M.; Higgs, B.W.; Weeks, D.E.; Ashokkumar, C.; Duerr, R.H.; Sun, Q. NOD2 gene polymorphism rs2066844 associates with need for combined liver-intestine transplantation in children with short-gut syndrome. Am. J. Gastroenterol. 2011, 106, 157-165.
48. Saner, F.H.; Nowak, K.; Hoyer, D.; Rath, P.; Canbay, A.; Paul, A. A non-interventional study of the genetic polymorphisms of NOD2 associated with increased mortality in non-alcoholic liver transplant patients. BMC Gastroenterol. 2014, 14, 4.
49. Van Gelder, T.; van Schaik, R.H.; Hesselink, D.A. Practicability of pharmacogenetics in transplantation medicine. Clin. Pharmacol. Ther. 2014, 95, 262-264.
50. Pallet, N.; Jannot, A.S.; El Bahri, M.; Etienne, I.; Buchler, M.; de Ligny, B.H.; Choukroun, G.; Colosio, C.; Thierry, A.; Vigneau, C.; et al. Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations. Am. J. Transplant. 2015, 15, 800-805.
51. Shi, W.L.; Tang, H.L.; Zhai, S.D. Effects of the CYP3A4*1B genetic polymorphism on the pharmacokinetics of tacrolimus in adult renal transplant recipients: A meta-analysis. PLoS ONE 2015, 10, e0127995.
52. Sombogaard, F.; van Schaik, R.H.; Mathot, R.A.; Budde, K.; van der Werf, M.; Vulto, A.G.; Weimar, W.; Glander, P.; Essioux, L.; van Gelder, T. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism. Pharmacogenet. Genomics 2009, 19, 626-634.
53. Shah, S.; Harwood, S.M, Döhler, B, Opelz, G, Yaqoob, M.M. Inosine monophosphate dehydrogenase polymorphisms and renal allograft outcome. Transplantation 2012, 94, 486-491.
54. Bosó, V.; Herrero, M.J.; Bea, S.; Galiana, M.; Marrero, P.; Marques, M.R.; Hernández, J.; Sanchez-Plumed, J.; Poveda, J.L.; Alino, S.F. Increased hospital stay and allograft dysfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285. Drug Metab. Dispos. 2013, 41, 480-487.